Mediators of the effect of body mass index on coronary heart disease

Epidemiology

Volumn 26, Issue 2, 2015, Pages 153-162

  Lu, Yuan ^a   Hajifathalian, Kaveh ^a   Rimm, Eric B ^a,b   Ezzati, Majid ^c   Danaei, Goodarz ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY RISK; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; AGED; BLOOD; COMPLICATION; CORONARY DISEASE; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY DISEASE; EFFECT MODIFIER, EPIDEMIOLOGIC; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS;

EID: 84923999106     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000234     Document Type: Article

References (47)

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country- years and 9.1 million participants. Lancet. 2011; 377 (9765): 557-567.
2. Stevens GA, Singh GM, Lu Y, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012; 10: 22.
3. Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011; 377 (9771): 1085-1095.
4. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and causespecific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373 (9669): 1083-1096.
5. N i Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M; Asia Pacific Cohort Studies Collaboration. Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol. 2004; 33: 751-758.
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880.
7. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113 (6): 898-918.
8. Hu FB. Obesity Epidemiology. Oxford University Press; 2008.
9. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011; 377 (9765): 568-577.
10. Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011; 377 (9765): 578-586.
11. C arroll K, Majeed A, Firth C, Gray J. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med. 2003; 25: 29-35.
12. L averty AA, Bottle A, Majeed A, Millett C. Blood pressure monitoring and control by cardiovascular disease status in UK primary care: 10 year retrospective cohort study 1998-2007. J Public Health (Oxf). 2011; 33: 302-309.
13. R idker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014; 35: 1782-1791.
14. R idker PM, Rifai N, Clearfield M, et al; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344: 1959-1965.
15. G oldberg R, Horton E, Marcovina S, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005; 54: 1566-1572.
16. L u Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014; 383 (9921): 970-983.
17. R obins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992; 3: 143-155.
18. Pearl J. Direct and indirect effects. In: Proceedings of the Seventeenth Conference on Uncertainty and Artificial Intelligence. San Francisco: Morgan Kaufmann; 2001: 411-420.
19. VanderWeele TJ. Unmeasured confounding and hazard scales: sensitivity analysis for total, direct, and indirect effects. Eur J Epidemiol. 2013; 28: 113-117.
20. VanderWeele TJ. Causal mediation analysis with survival data. Epidemiology. 2011; 22: 582-585.
21. VanderWeele TJ. A three-way decomposition of a total effect into direct, indirect, and interactive effects. Epidemiology. 2013; 24: 224-232.
22. E smon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005; 131: 417-430.
23. Festa A, D'Agostino R Jr, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001; 25: 1407-1415.
24. R onksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011; 342: d671.
25. Vanderweele TJ. Mediation analysis with multiple versions of the mediator. Epidemiology. 2012; 23: 454-463.
26. L ange T, Hansen JV. Direct and indirect effects in a survival context. Epidemiology. 2011; 22: 575-581.
27. Vanderweele TJ. Explanation in Causal Inference: Methods for Mediation and Interaction. New York, NY: Oxford University Press; 2015.
28. Hafeman DM. "Proportion explained": a causal interpretation for standard measures of indirect effect? Am J Epidemiol. 2009; 170: 1443-1448.
29. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet. 2000; 355: 434-442.
30. L loyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle- aged adults: a prospective study of parents and offspring. JAMA. 2004; 291: 2204-2211.
31. L eander K, Hallqvist J, Reuterwall C, Ahlbom A, de Faire U. Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: results from the Stockholm Heart Epidemiology Program (SHEEP). Epidemiology. 2001; 12: 215-221.
32. le Cessie S, Debeij J, Rosendaal FR, Cannegieter SC, Vandenbroucke JP. Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology. 2012; 23: 551-560.
33. VanderWeele TJ, Valeri L, Ogburn EL. The role of measurement error and misclassification in mediation analysis: mediation and measurement error. Epidemiology. 2012; 23: 561-564.
34. MacMahon S. Antihypertensive drug treatment: the potential, expected and observed effects on vascular disease. J Hypertens Suppl. 1990; 8: S239-S244.
35. L aw MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994; 308: 363-366.
36. L awes CM, Parag V, Bennett DA, et al; Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 2004; 27: 2836-2842.
37. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens. 2003; 17: 223-230.
38. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002; 3: 85-101.
39. Kaufman JS, Maclehose RF, Kaufman S. A further critique of the analytic strategy of adjusting for covariates to identify biologic mediation. Epidemiol Perspect Innov. 2004; 1: 4.
40. Bogers RP, Bemelmans WJ, Hoogenveen RT , et al; BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007; 167: 1720-1728.
41. R obins JM, Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, Monenberghs G, eds. Longitudinal data analysis. Handbooks of modern statistical methods. Boca Raton: Chapman & Hall/CRC; 2009: 533-599.
42. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008; 359: 2105-2120.
43. Hernán MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes (Lond). 2008; 32 (Suppl 3): S8-S14.
44. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37: 1053-1059.
45. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287: 2570-2581.
46. A vin C, Shpitser I, Pearl J. Identifiability of path-specific effects. Department of Statistics, UCLA 2005.
47. L ange T, Rasmussen M, Thygesen LC. Assessing natural direct and indirect effects through multiple pathways. Am J Epidemiol. 2014; 179: 513-518.